SCHEMBL6268680

SCHEMBL6268680

CC(NC1OCCO1)c1ccccn1

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
IDH1 O75874 1/20 0.38
SLC6A2 P23975 1/20 0.37
SLC6A4 P31645 1/20 0.37
SLC6A3 Q01959 1/20 0.37
KCNA5 P22460 4/20 0.37
TSHR P16473 1/20 0.37
KCNE1 P15382 1/20 0.37
TP53 P04637 1/20 0.36
EGFR P00533 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
ADORA2A P29274 5/20 0.35
CHRM2 P08172 1/20 0.35
CHRM4 P08173 1/20 0.35
CHRM5 P08912 1/20 0.35
CHRM1 P11229 1/20 0.35
CHRM3 P20309 1/20 0.35
ADORA2B P29275 4/20 0.35
KCNH2 Q12809 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28470929 0.83 IDH1 (0.37) IDH1SLC6A2SLC6A4SLC6A3KCNA5
SCHEMBL2674706 0.78 GAA (0.47) IDH1SLC6A2SLC6A4SLC6A3KCNA5
SCHEMBL28472061 0.75 GAA (0.53) SLC6A2SLC6A4SLC6A3KCNA5TSHR
SCHEMBL28468764 0.75 GAA (0.57) SLC6A2SLC6A4SLC6A3KCNA5KCNE1
SCHEMBL5349302 0.73 SLC6A2 (0.48) SLC6A2SLC6A4SLC6A3KCNA5TSHR
SCHEMBL28469055 0.72 ADORA2A (0.39) TP53EGFRCYP1A2CYP3A4ADORA2A
SCHEMBL28464903 0.72 ADORA2A (0.39) TP53EGFRCYP1A2CYP3A4ADORA2A
SCHEMBL3360610 0.72 ALDH1A1 (0.50) IDH1SLC6A2SLC6A4SLC6A3KCNA5
SCHEMBL13081517 0.71 SLC6A2 (0.47) SLC6A2SLC6A4SLC6A3KCNA5TSHR
SCHEMBL125581 0.71 SLC6A2 (0.47) SLC6A2SLC6A4SLC6A3KCNA5TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1601648-A2 PROCESS FOR PREPARING PYRIDINE-SUBSTITUTED AMINO KETAL DERIVATIVES Sanofi-Aventis Deutschland GmbH (DE) 2005-12-07 EP disclosed
US-6916934-B2 Process for preparing pyridine-substituted amino ketal derivatives AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2005-07-12 US disclosed
WO-2004072026-A2 PROCESS FOR PREPARING PYRIDINE-SUBSTITUTED AMINO KETAL DERIVATIVES AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-08-26 WO disclosed
US-20040158073-A1 Process for preparing pyridine-substituted amino ketal derivatives AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040158073-A1 Process for preparing pyridine-substituted amino ketal derivatives KMO, PKN1, PKN2 IDH1 697/4885SLC6A2 4584/4885SLC6A4 4239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.